Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
WithdrawnPhase 4NCT00225342
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The principle objective of the trial is to compare rosiglitazone to gliclazide in patients with type 2 diabetes mellitus and chronic stable angina to see how the subjects' angina status changes. Angina status will be measured via exercise tolerance testing, 24-hour ECG testing and angina quality of life questionnaire.
Study details
- Official title
- Effects of Rosiglitazone and Sulphonylureas on Ischaemic Burden, Blood Pressure and Novel Risk Markers Inclusive of Vascular Function in Patients With Chronic Stable Angina and Type 2 Diabetes Mellitus: A Randomised, Double-Blinded Study.
- Conditions
- Angina Pectoris
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Rosiglitazone
- Drug: Gliclazide (Comparison drug)
- Sponsor
- University of Glasgow
- Collaborators
- GlaxoSmithKline
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic stable angina with ongoing symptoms. (The treatment goal being an improvement in symptoms) * Participants will have uncontrolled diabetes (Hba1c\>7.5) on metformin monotherapy (so the diabetes is not over treated) * Participants will be diabetic for less than 8 years. Exclusion Criteria: * Renal impairment (creatinine \>130mmol/l) * Hepatic Impairment (ALT\>70U/l, AST\>80U/l) * Any clinical signs of heart failure * Physical disability precluding treadmill exercise tolerance testing * Abnormal resting ECG (left or right bundle-branch block, left or right ventricular hypertrophy, ventricular preexcitation, Q-wave myocardial infarction, digitalis therapy) * Women of childbearing potential * Women who are breastfeeding
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00225342